Biomarkers in Young Patients With Acute Myeloid Leukemia
|ClinicalTrials.gov Identifier: NCT01138332|
Recruitment Status : Completed
First Posted : June 7, 2010
Last Update Posted : May 6, 2015
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in tissue samples from young patients with acute myeloid leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: western blotting Other: laboratory biomarker analysis|
- Determine the frequency of ligand-independent phosphorylation of Stat3 in a small cohort of samples from pediatric patients with acute myeloid leukemia including, but not limited to, samples known to express mutated c-kit.
- Measure the level of Stat3 phosphorylation in these samples after stimulation of three key cytokine receptors expressed on hematopoietic cells IL-6R, G-CSFR, and c-kit.
OUTLINE: Cryopreserved samples are analyzed for levels of various components of the Stat3 pathway via western blotting.
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||Stat3 Signaling Pathway Aberrancies in Pediatric AML|
|Study Start Date :||September 2009|
|Primary Completion Date :||March 2010|
|Study Completion Date :||March 2010|
- Correlations between levels of pY-Stat3 and levels of upstream cytokine receptors
- Association of constitutive and/or increased pY-Stat3 and c-kit genotype
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01138332
|Principal Investigator:||Michele S. Redell, MD, PhD||Texas Children's Cancer Center|